A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: A report from the southern network on adverse reactions (SONAR)

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 8, 2012, Pages 783-796

  Bennett, Charles L ^a,b,c,d   Spiegel, David M ^e   MacDougall, Iain C ^f   Norris, Le Ann ^a,c   Qureshi, Zaina P ^a,b,c   Sartor, Oliver ^g   Lai, Stephen Y ^h   Tallman, Martin S ⁱ   Raisch, Dennis W ^j   Smith, Sheila Weiss ^k   Silver, Samuel ^l   Murday, Alanna S ^a,c   Armitage, James O ^m   Goldsmith, David ⁿ  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c WJB Dorn VA Medical Center   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g TULANE UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF NEW MEXICO   (United States)

^k UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^l UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^m UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁿ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

darbepoetin; epoetin; erythropoiesis stimulating agents; peginesatide

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADVERSE OUTCOME; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG UTILIZATION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; UNITED STATES; VASCULAR ACCESS; VENOUS THROMBOEMBOLISM;

ERYTHROPOIETIN; HUMANS; NEOPLASMS; PEPTIDES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84868567135     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328884     Document Type: Review

References (52)

1. Besarab A., Bolton W. K., Browne J. K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med: 1998; 339 9 584 590 (Pubitemid 28385655)
2. Pfeffer M., Burdmann E. A., Cooper D. E., et al. A trial of darbepoetin-alfa in type 2 diabetes and chronic kidney disease. N Engl J Med: 2009; 361 1 14
3. FDA Briefing Document on Peginesatide for the Oncologic Drug Advisory Committee (ODAC) December 7, 2011. Available at: http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/ oncologicdrugsadvisorycommittee/ucm282292.pdf. Accessed April 4, 2012
4. Leyland-Jones B. BEST Investigators and Study Group Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol: 2003; 4 8 459 460 (Pubitemid 37009952)
5. Henke M., Laszig R., Rübe C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet: 2003; 362 9392 1255 1260 (Pubitemid 37324251)
6. Bennett C. L., Silver S. M., Djulbegovic B., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA: 2008; 299 8 914 924 (Pubitemid 351397066)
7. Wilson J., Yao G. L., Raftery J., et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess: 2007; 11 13 1 202, iii-iv
8. Bohlius J., Schmidlin K., Brillant C., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet: 2009; 373 9674 1532 1542
9. Glaspy J., Crawford J., Vansteenkiste J., et al. Erythropoiesis- stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer: 2010; 102 2 301 315
10. Tonelli M., Hemmelgarn B., Reiman T., et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ: 2009; 180 11 E62 -E71
11. Epogen package insert. Amgen, Inc. 2007. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/103234s5158ppi.pdf. Accessed May 2,: 2012
12. FDA Advisory Committee Briefing Document Reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with chronic renal failure. Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee. September 11, 2007. Available at: http://www.fda.gov/ ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf. Accessed May 2, 2012
13. Rizzo J. D., Somerfield M. R., Hagerty K. L., et al. American Society of Clinical Oncology; American Society of Hematology Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol: 2008; 26 1 132 149
14. Meeting Briefing Document ODAC Epoetin alfa and darbepoetin. 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-05- amgen.pdf. Accessed May 2, 2012
15. Epogen F. DA. (Epoetin alfa) For injection package insert. 2008. Available at: http://www.fda.gov/cder/foi/label/2008/103234s5195sPI.pdf. Accessed May 2,: 2012
16. Patient Medication Guide F. DA. Epogen (Epoetin alfa). 2008. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/ 103234s5195Medguide.pdf. Accessed May 2, 2012
17. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: cancer and chemotherapy-induced anemia. V.1.2009. Available at: http://www.nccn.org/professionals/physician-gls/PDF/anemia.pdf. Accessed May 2, 2012
18. US FDA FDA approves a risk evaluation and mitigation strategy (REMS) to ensure the safe use of erythropoiesis-stimulating agents (ESAs). 2010. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm200847.htm. Accessed May 2, 2012
19. Rizzo J. D., Brouwers M., Hurley P., et al. American Society of Clinical Oncology; American Society of Hematology American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol: 2010; 28 33 4996 5010
20. European Medicines Agency Public Statement. Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease. October 2007. Available at: http://www.emea.europa.eu/pdfs/human/press/pus/49618807en.pdf. Accessed May 2, 2012
21. Aapro M., Spivak J. L. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist: 2009; 14 01 6 15
22. Medicines and Healthcare products Regulatory Agency (MHRA) Conclusions from the Committee for Medicinal Products for Human Use (CHMP) - Review of safety of erythropoiesis stimulating agents (ESAs) in patients with anaemia resulting from renal insufficiency or chemotherapy in cancer patients. 2008. Available at: http://www.mhra.gov.uk/home/groups/pl-p/documents/ websiteresources/con023076.pdf. Accessed May 2, 2012
23. National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Guidance-Epoetin Alfa, Epoetin Beta, and Darboepoetin Alfa for Cancer Treatment Induced Anaemia. London, UK National Institute for Health and Clinical Excellence (NICE): 2008;. Available at: http://www.nice.org.uk/nicemedia/pdf/ TA142Guidance.pdf. Accessed
24. Health Canada Important safety information and new prescribing information for the erythropoiesis-stimulating agents, aranesp (darbepoetin alfa) and EPREX (epoetin alfa). 2007. Available at: http://www.hc-sc.gc.ca/dhp- mps/alt-formats/pdf/medeff/advisories-avis/public/2007/aranesp-eprex-pc-cp-eng. pdf. Accessed May 2, 2012
25. Tonelli M., Lloyd A., Lee H., et al. Overview of systematic review and economic evaluation of erythropoiesis stimulating agents for anemia of cancer or of chemotherapy (technology overview number 51). Ottawa Canadian Agency for Drugs and Technologies in Health: 2009
26. Singh A. K., Szczech L., Tang K. L., et al. CHOIR Investigators Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med: 2006; 355 20 2085 2098 (Pubitemid 44749317)
27. Drüeke T. B., Locatelli F., Clyne N., et al. CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med: 2006; 355 20 2071 2084 (Pubitemid 44749316)
28. Cotter D. J., Stefanik K., Zhang Y., Thamer M., Scharfstein D., Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol: 2004; 57 10 1086 1095 (Pubitemid 39446648)
29. KDOQI KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 Update of Hemoglobin Target. Am J Kidney Dis: 2007; 50 3 471 530
30. Phrommintikul A., Haas S. J., Elsik M., Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet: 2007; 369 9559 381 388 (Pubitemid 46188479)
31. Zhang Y., Thamer M., Kaufman J. S., Cotter D. J., Hernán M. A. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int: 2011; 80 6 663 669
32. KDOQI KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis: 2007; 50 3 471 530
33. US FDA Center for Drug Evaluation and Research. Cardiovascular and Renal Drugs Advisory Committee meeting. 2008. Available at: http://www.fda.gov/ohrms/ dockets/ac/08/transcripts/2008-4390t1-part1.PDF. Accessed May 2, 2012
34. Epogen F. DA. (Epoetin alfa) For injection package insert. November 19, 2008. Available at: http://www.fda.gov/cder/foi/label/2008/103234s5195sPI.pdf. Accessed May 2, 2012
35. US FDA Center for Drug Evaluation and Research. Cardiovascular and Renal Drugs Advisory Committee meeting. 2010. Available at: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM238530.pdf. Accessed May 2, 2012
36. US FDA Center for Drug Evaluation and Research. Cardiovascular and Renal Drugs Advisory Committee meeting. 2011. Available at: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM256586.pdf. Accessed May 2, 2012
37. Epogen package insert FDA. 2010. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/label/2010/103234s5199lbl.pdf. Accessed May 2, 2012
38. Epogen/Procrit label. June 24, 2011. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/103234Orig1s5166-103234Orig1s5266lbl.pdf. Accessed May 2, 2012
39. EMA summary of product characteristics Abseamed (Epoetin alfa). October 12, 2009. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Procedural-steps-taken-and-scientific-information-after-authorisation/ human/000726/WC500028289.pdf. Accessed April 4, 2012
40. Locatelli F., Aljama P., Canaud B., et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant: 2010; 25 9 2846 2850
41. National Institute for Health and Clinical Excellence (NICE) Appraisal Consultation Document - Erythropoietin for anaemia induced by cancer treatment. 2011. http://www.nice.org.uk/guidance/index.jsp?action=article&r=true&o= 34940. Accessed May 2, 2012
42. Manns B. J., White C. T., Madore F., et al. Introduction to the Canadian Society of Nephrology clinical practice guidelines for the management of anemia associated with chronic kidney disease. Kidney Int Suppl: 2008; 110 S1 S3
43. Report T Canadian Agency for Drugs and Technology in Health. Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation. 2009. Available at: http://www.cadth.ca/media/pdf/H0468-Erythropoiesis-stimulating-agents-tr-e.pdf. Accessed May 2, 2012
44. Bennett C. L., McKoy J. M., Henke M., et al. Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park): 2010; 24 3 260 268
45. McFarlane P. A., Pisoni R. L., Eichleay M. A., Wald R., Port F. K., Mendelssohn D. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int: 2010; 78 2 215 223
46. Regidor D., McClellan W. M., Kewalramani R., Sharma A., Bradbury B. D. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Nephrol Dial Transplant: 2011; 26 5 1583 1591
47. Goldsmith D. J., Covic A. C. Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer. Kidney Int: 2011; 80 3 237 239
48. Palmer S. C., Navaneethan S. D., Craig J. C., et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med: 2010; 153 1 23 33
49. Medical Technology and Practice Patterns Institute (MTPPI) Citizen's petition. 2009. Available at: http://www.mtppi.org/new/FDA-2009-P-0426-0001.pdf. Accessed May 2, 2012
50. Cancer Care Ontario Epoetin alfa (Eprex) Janseen Ortho Formulary. Available at: http://www.cancercare.on.ca/search/default.aspx?q= formulary%20erythropoietin&type=0,6-76,6-40484|-1,1377-78. Accessed May 2, 2012
51. EMA Manufacturer's label. Annex II. 2007. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000726/WC500028282.pdf. Accessed May 2, 2012
52. Medical Technology and Practice Patterns Institute (MTPPI) Citizen's petition. 2009. Available at: http://www.mtppi.org/new/FDA-2009-P-0426-0001.pdf. Accessed May 2, 2012